News

ABL is delighted to announce the outcomes of a National Quality Control Study performed on the DeepChek® HIV Assays (RT/PR and INTEGRASE) on a panel human plasma samples collected in 2015 in 56 different labs in France. The overall agreement in the detection of HIV virus mutations exceeded 99% compa…

Advanced Biological Laboratories (ABL) S.A. and Technogenetics (TGX) today announced that they entered into an exclusive distributor agreement of the DeepChek® SingleRound Assay and software product lines in Italy. The DeepChek® SingleRound Assay product line combines target-specific PCR reagents wi…

ABL continues developing its technology offer with Nadis(r) technology as a specialized patient management system. Nadis is widely used in France, this completes the offer for the French market in plus of microbiology reagents and software.

ABL inked an agreement with Inserm on a test and related IP and know-how intended for viral hepatitis C.

ABL is pleased to invite you to attend the viral typing webinar held with Thermo Fisher Scientific about the combination of their next generation sequencing systems and the ABL DeepChek downstream analysis software, for HIV, HBV and HCV. Tuesday, 10th May 2016 — 5 pm CET / 4 pm GMT / 11 am EST Regis…

ABL inked a distribution agreement with Thermo Fisher Scientific for ViroScore and DeepChek, downstream analysis softwares for Sanger and Next Generation Sequencing respectively. These are also available on Thermo Fisher Cloud. See the press release.

ABL group is pleased to announce the launch of an early access program (EAP) of its first genotyping DeepChek® assay for HCV NS5B. Further reagents will come soon to complete ABL Group’s offer for Sanger and Next Generation Sequencing. These reagents will be completed with data analysis software, Vi…

Barcelona, 16th February 2015. Researchers from Vall d’Hebron Research Institute (VHIR) have developed a new deep sequencing methodology that accurately classifies the 7 confirmed genotypes of the hepatitis C (HCV) virus, and the different subtypes. The new system also allows, for the first time, to…

ABL is pleased to announce that its mark HepatiC® has now achieved registration with the United States Patent and Trademark Office on the Supplemental Register with N° 4,661,252. The HepatiC® software is a patient register to monitor HCV-infected patients in particular for ones using Direct Antivira…

University Hospitals (UH) Case Medical Center has signed an agreement with Advanced Biological Laboratories (ABL), to join efforts on the designing and validation of an HIV drug resistance and tropism assay based on next-generation sequencing (NGS). See the press release. See the press release. http…

Two new DeepChek® applications dedicated to viral hepatitis B (HBV) and hepatitis C (HCV) are now available in BaseSpace, the Illumina’s dedicated applications store and cloud-based informatics community dedicated to advancing genomic analysis. See the press release about BaseSpace and Illumina.

ABL will be participating to the next Illumina BaseSpace Worldwide Developers Conference (WWDC) in San Francisco on the 8th and 9th of December 2014. View more

ABL S.A, The University of Hong Kong and The Hong Kong Polytechnic University are launching their collaborative tuberculosis (TB) project to develop a deep-sequencing assay and its tailored bio-informatics pipeline. View more

ABL is pleased to announce a new collaboration with the New Zealand Liver Transplant Unit and LabPlus at Auckland City Hospital. This will evaluate the susceptibility to develop Hepatocellular Carcinoma (HCC) during 30 years follow-up, based on key baseline genomic variations of HBV in a large cohor…

ABL and Mayo Medical Laboratories will develop novel innovative LDT and related IT in the field of virology. More details available here.